[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myofascial-pain-syndrome---neck\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myofascial-pain-syndrome---neck":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,82,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100647955","effectiveness-of-mitragynine-topical-patch-for-pain-reduction-in-myofascial-pain-syndrome-100647955",false,"NCT07713771","Effectiveness of Mitragynine Topical Patch for Pain Reduction in Myofascial Pain Syndrome","Effectiveness of Mitragynine Topical Patch From Kratom for Pain Reduction in Myofascial Pain Syndrome of Upper Trapezius Muscle: Double Blinded Placebo, Randomized Controlled Trial","mirtapatch","Inclusion Criteria:\n\n* \\- Patients aged 18-50 years.\n* Experiencing neck or shoulder pain for more than 3 months.\n* Diagnosed with myofascial pain syndrome, with the most tender trigger point located in the upper trapezius muscle and a pain score between 30-60 mm measured using the Visual Analogue Scale (VAS).\n\nExclusion Criteria:\n\n* \\- History of other neck-related conditions (e.g., whiplash injury, cervical radiculopathy, fibromyalgia syndrome, cervical spine surgery and\u002For fracture).\n* History of systemic diseases (e.g., rheumatism, multiple sclerosis, cervical myelopathy), hepatitis, liver failure, or kidney disease (serum creatinine \\> 2.0 mg\u002FdL).\n* Symptoms or conditions contraindicating the use of patches, such as wounds or infections at the painful site.\n* History of allergy to paracetamol or kratom.\n* History of allergy to adhesive patches\u002Fplasters.\n* Pregnant or breastfeeding women.\n* Receipt of treatment with analgesics other than paracetamol, physical therapy, dry needling\u002Facupuncture, massage, or topical medications within the previous week.\n* Individuals who are unable to read or write.","ALL","18 Years","50 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Myofascial Pain Syndrome (MPS) is one of the leading causes of both acute and chronic musculoskeletal pain encountered in clinical practice.¹ The most common presentation is low back pain, followed by pain in the neck and scapular regions.² These symptoms significantly affect quality of life and work performance. A common site involved in neck pain syndrome is the trapezius muscle, which may cause pain in the shoulder, neck, and occipital region. In some patients, neurological symptoms such as goosebumps or dizziness may also occur.³ Pain can occur in individuals of all age groups and may be either acute or chronic. It can arise from injuries or various diseases. Pain may result from different pathologies, including nociceptive pain, neuropathic pain, or a combination of both. Current medical treatment guidelines include both conventional medications and herbal extract-based therapies. In the 2022 National List of Essential Herbal Medicines of Thailand, several herbal formulations are indicated for pain relief. Oral preparations include Khasai Sen, Thorani Sandhakhat, and Ya Phasom Thao Wan Priang, while topical preparations include chili-based formulations, plai preparations, and plai oil. These remedies are indicated for the relief of body aches and muscle pain.⁶ Kratom, or \\*Mitragyna speciosa\\* (Korth.) Havil., is a plant belonging to the Rubiaceae family. In southern Thailand, it is commonly known as \"Thom.\" Kratom leaves contain a variety of chemical constituents, including alkaloids, flavonoids, triterpenes, and phenolic compounds. Among these, indole alkaloids represent the major group. The principal active compound is mitragynine, which accounts for approximately two-thirds of the total alkaloid content, or about 66% by weight.⁷ Pharmacologically, orally administered mitragynine affects both the autonomic and central nervous systems. It possesses analgesic properties through binding to opioid receptors. Additionally, it reduces pain signal transmission to the brain via the noradrenergic and serotonergic systems.⁸ The mitragynine pain-relief patch used in this study is a product containing kratom extract formulated to deliver 10 milligrams of mitragynine per patch. It is designed as a topical patch, allowing the active ingredient to be absorbed into the outer layers of the skin without entering the bloodstream.¹¹ The patch consists of sodium alginate, pectin, and agar, which are naturally derived polymers commonly used as pharmaceutical excipients. The hypothesis of this study is that this locally acting \"mitragynine pain-relief patch\" can reduce pain and inflammation through the TRPV1 receptor mechanism described above.\n\nNeck, shoulder, and upper back pain are among the most common reasons patients attend general practice, orthopedic, and rehabilitation clinics. Patients with chronic myofascial pain syndrome (defined as pain persisting for more than three months) may be treated using various approaches depending on symptom severity, accessibility of services, and individual suitability. These approaches include oral medications, topical agents, local injections, acupuncture, physical therapy, and muscle stretching exercises.\n\nMany patients may have contraindications to oral medications, acupuncture, or regular attendance at physical therapy sessions, which can negatively affect their overall quality of life. Currently, topical medications are commonly prescribed for these patients at Hospital; however, treatment outcomes are often suboptimal. Moreover, most topical preparations produce a warming effect and may easily cause skin irritation, particularly in elderly patients with fragile skin. If the mitragynine pain-relief patch demonstrates effective pain reduction, it may be further developed as an alternative treatment option for these patients.\n\nThe objective of this study is to evaluate the efficacy of a mitragynine-containing kratom pain-relief patch in patients with myofascial pain syndrome, compared with a placebo patch (a patch containing only the base formulation without kratom extract), and to determine whether there is a difference in pain-relief response between the two groups and, if so, how that difference manifests.",[28,29],"Topical Analgesia","Myofascial Pain Syndrome - Neck",[31,32,33,34],"mirtagynine","kratom patch","topical patch","pain reduction","NOT_YET_RECRUITING","2026-08-05",{"date":38,"type":39},"2026-08-10","ACTUAL",{"date":41,"type":22},"2026-10-01",{"date":43,"type":22},"2029-10-31",{"name":45,"class":46},"Prince of Songkla University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100645479","effects-of-different-myofascial-release-techniques-on-function-in-chronic-non-specific-neck-pain-100645479","NCT07694882","Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain","Investigation of the Effects of Different Myofascial Release Techniques on Functional Outcomes in Individuals With Chronic Non-Specific Neck Pain","MFR \u002F CNNP","Inclusion Criteria:\n\n* Neck pain persisting for at least 3 months and diagnosed as chronic non-specific neck pain by a specialist physician\n* Aged between 18 and 45 years\n* Perceived pain affecting daily living activities (VAS at least 3)\n* Presence of myofascial trigger points in the upper-quarter muscles\n\nExclusion Criteria:\n\n* Specific serious cervical spine pathology (radiculopathy, myelopathy, severe nerve root compression, spondylosis, and similar)\n* History of rheumatologic, neurologic, or systemic disease (for example, acute inflammation, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, fibromyalgia, or cancer)\n* History of trauma, fracture, or surgery involving the neck, shoulder, or upper extremity\n* Pregnancy or breastfeeding\n* Any diagnosed psychiatric disorder (for example, major depression or anxiety disorder) or regular use of psychopharmacological medication\n* Use of systemic analgesics, NSAIDs, or muscle relaxants within the last 7 days for pain control\n* Any physiotherapy, manual therapy, or injection treatment to the neck region within the last 3 months","45 Years",{"count":58,"type":22},84,[60],"NA","This single-center, three-arm randomized controlled trial compares the effects of different myofascial release techniques, combined with a structured exercise program, on functional outcomes in individuals with chronic non-specific neck pain (CNNP).\n\nEligible participants (aged 18 to 45 years, neck pain for at least 3 months, pain intensity VAS at least 3, and myofascial trigger points in the upper-quarter muscles) are allocated by simple randomization into three groups:\n\n* Conventional Therapy Group: hot pack, conventional TENS, and a structured exercise program.\n* Manual Myofascial Release Group: conventional therapy plus therapist-applied manual myofascial release.\n* Self-Myofascial Release Group: conventional therapy plus supervised self-applied myofascial release using a duo-ball, balls, and a massage stick\u002Fcane.\n\nAll interventions are delivered 3 days per week for 6 weeks. The primary outcome is pain intensity. Secondary outcomes include pressure pain threshold and tolerance, cervical range of motion, muscle stiffness, craniovertebral angle, cervical proprioception, muscle strength and endurance, disability, neck awareness, multidimensional biopsychosocial status, sleep quality, quality of life, and kinesiophobia. The aim is to determine whether manual or self-applied myofascial release, added to exercise, produces greater functional improvement in people with chronic non-specific neck pain.",[63,64,65,29],"Chronic Neck Pain","Non-specific Neck Pain","Myofascial Trigger Points",[67,68,69,70,71,72],"chronic non-specific neck pain","myofascial release","manual therapy","trigger points","therapeutic exercise","physiotherapy","RECRUITING","2026-07-13",{"date":76,"type":39},"2026-07-14",{"date":76,"type":39},{"date":79,"type":22},"2026-12-31",{"name":81,"class":46},"Eastern Mediterranean University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100504668","low-energy-ultrasound-electrical-and-magnetic-field-stimulation-in-therapy-resistant-myofascial-pain-syndrome-100504668","NCT05851326","Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome","A Combination of Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Patients With Therapy-Resistant Myofascial Pain Syndrome: A Randomized, Controlled, Double-Blind Multi-Center Study","Inclusion Criteria:\n\n* Male or female aged 18 to 99 years at screening\n* Patient has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures\n* Patient is suffering from one of the following chronic pain conditions originating from myofascial pain:\n\n  * low back pain\n  * tension headache\n  * neck pain\n\nhaving been persisting for a minimum of 3 months and where myofascial pain syndrome is the pre-dominant cause for pain.\n\n* Patient is constant with respect to pain treatment for 1 week during the screening phase\n* A daily average NRS \\>= 4 on 4 out of 7 days in the screening phase\n* Compliance with the daily status reporting requirements as demonstrated\n\nExclusion Criteria:\n\n* Patients with active implants\n* Allergy against rescue medication used during the study\n* Pregnancy\n* Mental or physical impairments that represent a source of risk for handling the device\n* Patients with cerebral spams (epilepsy)\n* Patients with psychiatric diseases or somatoform pain disorders\n* Patients with oral morphine equivalent of more than 120mg daily dose\n* Patients taking centrally acting muscle relaxants like Sirdalud or benzodiacepines\n* Patients with a contraindication against NSAID's\n* Presence of artificial joints made from methylmethacrylate or polyethylene at stimulation site\n* Presence of ferromagnetic metal implants at stimulation site, especially aneurysm clips, dental implants, etc.","99 Years",{"count":91,"type":22},126,[60],"Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain syndrome.\n\nMyofascial pain syndrome is a prevalent pain condition in the adult population and a common cause of pain and dysfunction in the musculoskeletal system. It is a trigger point-induced regional musculoskeletal pain disorder affecting one or more muscles or groups of muscles.\n\nSonodyn is a handheld medical device that combines low-energy ultrasound, electrical and magnetic field stimulation for non-invasive transcutaneous treatment of chronic myofascial pain syndrome. Sonodyn is a battery-operated, rechargeable stimulation device to be placed over specific trigger points for associated pain patterns in the human body. It emits ultrasound, electrical and magnetic stimulation signals with a pre-defined set of parameters for each of the independently operated power sources.\n\nThe study will follow a prospective, randomized, sham-controlled, double-blind parallel group design. It will be conducted as a multi-center investigation at 6 sites in Austria and Switzerland. Patients are randomized in a 2:1 ratio into Treatment and Control.\n\n* Active Sonodyn therapy (Treatment)\n* No therapy (Sham Control)\n\nTwo types of Sonodyn devices will be used: a fully functional one for Therapy arm patients that can deliver stimulation, and a non-functional one for Control arm patients that cannot convey any energy signals to the device output. The devices will look fully identical.\n\nRandomization will be stratified by study site, pain diagnosis and sex of the patient.\n\nFor each subject, after a screening phase of 1 week, patients will be treated for 3 weeks with a follow-up of additional 8 weeks, adding up to 12 weeks. During treatment patients will activate their device 3 times a day for 10 minutes each.\n\nDuring screening, treatment and follow-up period, all patients will twice per day report the average and maximum intensity of their pain Numeric Rating Scale (NRS). Patients will also enter the date, amount, and time of intake of rescue medication, if applicable.\n\nThe primary objective of this study is to assess the impact on pain. Secondary objectives are to compare the performance between active therapy and sham, as well as to correlate changes in pain intensity with other pain related scales.",[95,29,96],"Myofascial Pain Syndrome - Lower Back","Myofascial Pain Syndrome - Tension Headache",[98,99,100,101,102],"Myofascial Pain Syndrome","Low-Energy Stimulation","Ultrasound, Electrical and Magnetic Field Stimulation","Transcutaneous Pain Therapy","Chronic Pain","2026-04-21",{"date":105,"type":39},"2026-04-23",{"date":107,"type":39},"2023-05-25",{"date":109,"type":22},"2027-06",{"name":111,"class":112},"Sobet AG","INDUSTRY",6,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":47},"100600535","comparing-physical-therapy-interventions-on-craniovertebral-angle-cva-in-cervical-myofascial-pain-syndrome-mps-100600535","NCT07098754","Comparing Physical Therapy Interventions on Craniovertebral Angle (CVA) in Cervical Myofascial Pain Syndrome (MPS)","Comparative Analysis of Different Physiotherapy Interventions on Craniovertebral Angle in Individuals With Myofascial Pain Syndrome and Radiculopathy: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: Participants must be between 20 and 40 years old.\n2. Gender: Both genders, Male and Female have equal chance of selection as participant in the study.\n3. Diagnosis: Participants must have a confirmed diagnosis of myofascial pain syndrome (MPS), altered cervical posture, restricted range of motion of cervical spine due to muscular spasm etc, altered craniovertebral angle, pain in cervical region or upper extremity and\u002For radiculopathy by a qualified healthcare professional, based on standardized diagnostic criteria (e.g., clinical examination, imaging studies).\n4. Severity: Participants should have mild to moderate symptoms of MPS and\u002For radiculopathy, as determined by the assessing healthcare provider.\n5. Willingness to Participate: Participants must be willing and able to comply physically and mentally with the study procedures, including attending scheduled physiotherapy sessions and completing outcome assessments.\n6. Informed Consent: Participants will have to provide written informed consent mendatorily to be selected as participant in the study after receiving detailed information about the study aims, procedures, potential risks, and benefits.\n\nExclusion Criteria:\n\n1. Severe Comorbidities: Participants with severe comorbidities or medical conditions that may interfere with their ability to participate in the study or confound the interpretation of results will be excluded. C1, C2 compression… vertigo\n2. Surgeries: Participants who have undergone surgeries in the cervical or head region in past will be excluded due to potential confounding effects on outcomes.\n3. Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with certain physiotherapy modalities and the need for specialized considerations in this population.\n4. Contraindications: Participants with contraindications to specific physiotherapy modalities included in the study protocol (e.g., contraindications to dry needling, electrotherapy) will be excluded to ensure participant safety.\n5. Inability to Attend Sessions: Participants who are unable to attend scheduled physiotherapy sessions due to logistical constraints (e.g., transportation issues, scheduling conflicts) will be excluded.\n6. Cognitive Impairment: Participants with significant cognitive impairment or communication difficulties that may impede their ability to understand and follow study instructions will be excluded.\n7. Participation in Other Research: Participants who are currently participating in other research studies involving treatment interventions for MPS and\u002For radiculopathy will be excluded to avoid potential confounding effects on outcomes and treatment adherence.\n8. Malignancies: participants suffering from any kind of malignancies will be excluded from the study.\n9. Trauma: Participants having a history of trauma and fractures in head and neck region will also be excluded from the study.","20 Years","40 Years",{"count":124,"type":22},100,[60],"Myofascial pain syndrome (MPS) and radiculopathy are prevalent musculoskeletal conditions that afflict a substantial portion of the population, causing significant discomfort and impairments in daily functioning. MPS is characterized by localized muscle pain, trigger points, and referred pain, often accompanied by stiffness and restricted range of motion. A common feature shared by individuals with MPS and radiculopathy is the presence of postural abnormalities and balance impairments . The craniovertebral angle, which reflects the relationship between the head and neck, is often compromised in these individuals due to muscle imbalances, pain-related guarding, and structural changes in the spine. Various physiotherapy modalities, including dry needling, manual mobilization and soft tissue release, trigger point therapy, stretching, cupping therapy, and electrotherapy, have been utilized in clinical practice, but their relative efficacy in improving the craniovertebral angle and alleviating symptoms in individuals with MPS and radiculopathy has not been comprehensively compared. Understanding the underlying mechanisms and comparative effectiveness of various physiotherapy interventions is essential for guiding evidence-based clinical decision-making and optimizing treatment outcomes for individuals with MPS and radiculopathy. By elucidating the effects of different treatment modalities on the craniovertebral angle and associated outcomes, this research endeavor aims to contribute to the development of more tailored and effective physiotherapy approaches for improving the well-being of individuals affected by these debilitating musculoskeletal conditions.",[29],[129,130,131,132],"myofascial pain syndrome","dry needling in myofascial pain syndrome","cupping therapy in myofascial pain syndrome","best intervention for myofascial pain syndrome","2025-07-29",{"date":135,"type":39},"2025-08-01",{"date":137,"type":39},"2025-03-15",{"date":139,"type":22},"2025-09-15",{"name":141,"class":46},"National Orthopedic and General Hospital"]